Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
Ando C, Ichihara E, Nishi T, Morita A, Hara N, Takada K, Nakasuka T, Watanabe H, Kano H, Nishii K, Makimoto G, Kondo T, Ninomiya K, Fujii M, Kubo T, Ohashi K, Matsuoka KI, Hotta K, Tabata M, Maeda Y, Kiura K. Ando C, et al. Among authors: makimoto g. Cancer Sci. 2023 Nov;114(11):4343-4354. doi: 10.1111/cas.15958. Epub 2023 Sep 15. Cancer Sci. 2023. PMID: 37715310 Free PMC article.
Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
Kudo K, Ohashi K, Makimoto G, Higo H, Kato Y, Kayatani H, Kurata Y, Takami Y, Minami D, Ninomiya T, Kubo T, Ichihara E, Sato A, Hotta K, Yoshino T, Tanimoto M, Kiura K. Kudo K, et al. Among authors: makimoto g. Mol Oncol. 2017 Jun;11(6):670-681. doi: 10.1002/1878-0261.12063. Epub 2017 May 2. Mol Oncol. 2017. PMID: 28388009 Free PMC article.
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.
Tamura T, Kato Y, Ohashi K, Ninomiya K, Makimoto G, Gotoda H, Kubo T, Ichihara E, Tanaka T, Ichimura K, Maeda Y, Hotta K, Kiura K. Tamura T, et al. Among authors: makimoto g. Biochem Biophys Res Commun. 2018 Jan 1;495(1):360-367. doi: 10.1016/j.bbrc.2017.10.175. Epub 2017 Oct 31. Biochem Biophys Res Commun. 2018. PMID: 29101033
Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol.
Makimoto G, Ichihara E, Hotta K, Ninomiya K, Oze I, Minami D, Ninomiya T, Kubo T, Ohashi K, Tabata M, Maeda Y, Kiura K. Makimoto G, et al. Acta Med Okayama. 2018 Jun;72(3):319-323. doi: 10.18926/AMO/56080. Acta Med Okayama. 2018. PMID: 29926012 Free article. Clinical Trial.
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K. Kato Y, et al. Among authors: makimoto g. Cancer Sci. 2018 Oct;109(10):3149-3158. doi: 10.1111/cas.13752. Epub 2018 Sep 11. Cancer Sci. 2018. PMID: 30053332 Free PMC article.
Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab.
Senoo S, Ninomiya T, Makimoto G, Nishii K, Kano H, Watanabe H, Hata Y, Kubo T, Tanaka T, Hotta K, Maeda Y, Kiura K. Senoo S, et al. Among authors: makimoto g. Intern Med. 2019 Apr 1;58(7):985-989. doi: 10.2169/internalmedicine.0890-18. Epub 2018 Dec 18. Intern Med. 2019. PMID: 30568113 Free PMC article.
58 results